LDL-apheresis and concomitant ACE-inhibitor therapy
- 1 January 1994
- journal article
- other
- Published by Elsevier in Atherosclerosis
- Vol. 105 (1) , 115-116
- https://doi.org/10.1016/0021-9150(94)90013-2
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- ACE inhibitors and LDL-apheresis with dextran sulphate adsorptionThe Lancet, 1992
- Anaphylactoid reactions, LDL apheresis with dextran sulphate, and ACE inhibitorsThe Lancet, 1992
- Assessment of the Biocompatibility and Long‐Term Effect of LDL‐Apheresis by Dextran Sulfate‐Cellulose ColumnArtificial Organs, 1992
- Changes in Coagulation Factors by Passage through a Dextran Sulfate Cellulose Column during Low-Density Lipoprotein ApheresisThe International Journal of Artificial Organs, 1992
- Anaphylactoid reactions in hemodialysis patients treated with the AN69 dialyzerKidney International, 1991
- Hoe 140 a new potent and long acting bradykinin‐antagonist: in vivo studiesBritish Journal of Pharmacology, 1991
- Hoe 140 a new potent and long acting bradykinin‐antagonist: in vitro studiesBritish Journal of Pharmacology, 1991
- LDL-apheresis: results of longterm treatment and vascular outcomeAtherosclerosis, 1991
- Kinins act on B1 or B2 receptors to release conjointly endothelium‐derived relaxing factor and prostacyclin from bovine aortic endothelial cellsBritish Journal of Pharmacology, 1989
- Pharmacological Studies of FUT-175, Nafamstat Mesilate I. Inhibition of Protease Activity in in Vitro and in Vivo ExperimentsThe Japanese Journal of Pharmacology, 1984